A randomised, double-blind placebo controlled study of subcutaneous ketamine in the management of cancer pain

Dataset includes: - data for 185 participants with pain caused by cancer (93 allocated to Ketamine, 92 allocated to placebo). Treatment period over 5 days, with follow-up for 4 weeks post treatment. Data available for demographic data, primary outcome as Brief Pain Inventory score, quality of life (as EORTC QLQ -C30 and FACIT-PAL), performance status (as AKPS), opioid use, Global Impression of Change, adverse events (as NCI CTCAE V3.0), carer QOL (as Caregiver QOLC), Medicare Australia data, and survival.